128 related articles for article (PubMed ID: 1747725)
21. Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.
Boccardo F; Cannata D; Rubagotti A; Guarneri D; Decensi A; Canobbio L; Curotto A; Martorana G; Pegoraro C; Selvaggi F
J Clin Oncol; 1994 Jan; 12(1):7-13. PubMed ID: 8270987
[TBL] [Abstract][Full Text] [Related]
22. [Prophylaxis of transitional cell carcinoma of the bladder G1-G2; pTa-pT1 with mitomycin C or interferon alpha-2a. Preliminary data].
Vecchioli Scaldazza C
Minerva Urol Nefrol; 1993 Sep; 45(3):117-21. PubMed ID: 8278878
[TBL] [Abstract][Full Text] [Related]
23. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
Flamm J; Kühnel W; Dona S
Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
[TBL] [Abstract][Full Text] [Related]
24. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
25. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up.
Mohanty NK; Malhotra V; Nayak RL; Arora RP
J Chemother; 2002 Apr; 14(2):194-7. PubMed ID: 12017377
[TBL] [Abstract][Full Text] [Related]
26. Use of intracavitary interferon-alpha-2b in the prophylactic treatment of patients with superficial bladder cancer.
Moltó L; Alvarez-Mon M; Carballido J; Olivier C; Gimeno F; Manzano L
Cancer; 1995 Jun; 75(11):2720-6. PubMed ID: 7743476
[TBL] [Abstract][Full Text] [Related]
27. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
Papatsoris AG; Deliveliotis C; Giannopoulos A; Dimopoulos C
Urol Int; 2004; 72(4):284-91. PubMed ID: 15153724
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
Okamura T; Tozawa K; Yamada Y; Sakagami H; Ueda K; Kohri K
J Urol; 1996 Sep; 156(3):967-71. PubMed ID: 8709375
[TBL] [Abstract][Full Text] [Related]
30. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic oral UFT therapy for superficial bladder cancer.
Kubota Y; Hosaka M; Fukushima S; Kondo I
Cancer; 1993 Mar; 71(5):1842-5. PubMed ID: 8448746
[TBL] [Abstract][Full Text] [Related]
32. [Clinical research on prevention of recurrence of superficial bladder cancer--comparative study on clinical efficacy of bleomycin intravesical instillation and bestatin].
Kumamoto Y; Tsukamoto T; Tamiya T; Takatsuka K; Furuya S; Yokoyama E; Honma A; Aoyama T; Tanda H; Kato S
Hinyokika Kiyo; 1985 Oct; 31(10):1861-83. PubMed ID: 2418659
[TBL] [Abstract][Full Text] [Related]
33. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
[TBL] [Abstract][Full Text] [Related]
34. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
35. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
Bercovich E; Deriu M; Manferrari F; Irianni G
Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
[TBL] [Abstract][Full Text] [Related]
36. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
37. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder.
Glashan RW
J Urol; 1990 Sep; 144(3):658-61. PubMed ID: 2201795
[TBL] [Abstract][Full Text] [Related]
38. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
39. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
[TBL] [Abstract][Full Text] [Related]
40. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Wu WJ; Ke HL; Yang YH; Li CC; Chou YH; Huang CH
J Urol; 2010 Jan; 183(1):56-61. PubMed ID: 19913833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
